Back to Search
Start Over
Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study.
- Source :
- Thoracic Cancer; Jul2024, Vol. 15 Issue 20, p1541-1552, 12p
- Publication Year :
- 2024
-
Abstract
- Background: To elucidate the treatment and surgery outcomes with or without perioperative therapies in Japanese patients with clinical stage III non‐small cell lung cancer (NSCLC) in real‐world settings. Methods: We performed subset analyses of the SOLUTION study, a multicenter, noninterventional, observational study of Japanese patients diagnosed with clinical stage III NSCLC, for those who started first‐line treatment (surgery±perioperative therapy) between January 2013 and December 2014 (study registration: UMIN000031385). Follow‐up data were obtained using medical records from diagnosis to March 1, 2018. Results: Of 149 eligible patients, 67 underwent surgery alone (median age 71 years) and 82 underwent surgery+perioperative therapy (median age 63 years). Lung resection was performed in 137 patients and the others underwent exploratory thoracotomy or other procedures. Perioperative therapies included adjuvant therapy only (n = 41), neoadjuvant therapy only (n = 24), and neoadjuvant+adjuvant therapy (n = 17). The median overall survival (OS) and 3‐year OS rate were 29.3 months and 44.0%, respectively, in patients who underwent surgery alone, and not reached and 61.1%, respectively, in patients who underwent surgery+perioperative therapy. The 3‐year progression‐free survival (PFS) and disease‐free survival (DFS) rates were 42.4% and 47.1%, respectively, in patients who underwent surgery+perioperative therapy and 28.5% and 28.9%, respectively, in patients who underwent surgery alone. In multivariable Cox regression, perioperative therapy was associated with improved OS (hazard ratio [95% confidence interval] 0.49 [0.29–0.81]), PFS (0.62 [0.39–0.96]), and DFS (0.62 [0.39–0.97]) versus surgery alone. Conclusions: Our study suggested that perioperative therapy may be associated with better survival among patients undergoing surgical treatment of clinical stage III NSCLC. [ABSTRACT FROM AUTHOR]
- Subjects :
- SURGERY
PATIENTS
THORACOTOMY
RESEARCH funding
SCIENTIFIC observation
TREATMENT effectiveness
CANCER patients
DESCRIPTIVE statistics
ADJUVANT chemotherapy
LONGITUDINAL method
RESEARCH
COMBINED modality therapy
LUNG cancer
TUMOR classification
COMPARATIVE studies
PROGRESSION-free survival
CONFIDENCE intervals
PERIOPERATIVE care
PNEUMONECTOMY
OVERALL survival
PROPORTIONAL hazards models
REGRESSION analysis
Subjects
Details
- Language :
- English
- ISSN :
- 17597706
- Volume :
- 15
- Issue :
- 20
- Database :
- Complementary Index
- Journal :
- Thoracic Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 178442425
- Full Text :
- https://doi.org/10.1111/1759-7714.15305